摘要
目的探讨硼替佐咪皮下注射治疗多发性骨髓瘤的临床效果。方法分析我院血液内科2012年3月~2017年6月收治的多发性骨髓瘤患者46例的临床资料,依据治疗方式不同进行分组,对照组(静脉注射硼替佐咪)23例和观察组(皮下注射硼替佐咪)23例。观察两组患者的临床疗效、不良反应发生情况。结果观察组患者的总缓解率为78.3%,高于对照组的56.5%,不良反应发生率为8.7%,低于对照组(26.1%)(P<0.05)。结论硼替佐咪皮下注射治疗多发性骨髓瘤的临床治疗总缓解率较高,不良反应少,值得临床推广应用。
Objective To explore the clinical effect of subcutaneous injection Bortezomib treating multiple myeloma.Methods Clinical data of 46 patients with multiple myeloma treated in Department of internal medicine of hematology of our hospital from March 2012 to June 2017 were analyzed,and patients were divided into the two group according to the different treatment method.The control group(intravenous injection of Bortezomib,n=23)and observation group(subcutaneous injection of Bortezomib,n=23).The clinical curative effect,the incidence of adverse reactions of patients in the two group were observed.Results The total remission rate of observation group(78.3%)was higher than than that of the control group(56.5%),the incidence of adverse reactions was of observation group(8.7%)was lower than that of the control group(26.1%)(P<0.05).Conclusion The total remission rate of clinical treatment of subcutaneous injection of Bortezomib treating multiple myeloma is high,and the incidence of adverse reaction is fewer.It is worthy of clinical promotion and application.The multiple myeloma patients by bortezomib hypodermic injection,clinical treatment total remission rate is high,adverse reactions rate is little,it is worth to be used.
作者
李荣
LI Rong(Department of Internal Medicine of Hematology,Liaohe Oilfield General Hospital,Liaoning Province,Panjin 124010,China)
出处
《中国当代医药》
2018年第8期40-42,共3页
China Modern Medicine
关键词
硼替佐咪
皮下注射
静脉注射
多发性骨髓瘤
Bortezomib
Subcutaneous injection
Intravenous injection
Multiple myeloma
